Canagliflozin
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Canagliflozin?
Summarize this article for a 10 year old
Canagliflozin, sold under the brand name Invokana among others, is a medication used to treat type 2 diabetes.[2] It is used together with exercise and diet.[2] It is not recommended in type 1 diabetes.[2] It is taken by mouth.[2]
Clinical data | |
---|---|
Pronunciation | /ˌkænəɡlɪˈfloʊzɪn/ KAN-ə-glif-LOH-zin |
Trade names | Invokana, Sulisent, Prominad, others |
Other names | JNJ-28431754; TA-7284; (1S)-1,5-anhydro-1-C-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl]}-4-methylphenyl)-D-glucitol |
AHFS/Drugs.com | Monograph |
MedlinePlus | a613033 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | SGLT2 inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 65% |
Protein binding | 99% |
Metabolism | Liver glucuronidation |
Elimination half-life | 11.8 (10–13) hours |
Excretion | 53% faecal and 33% kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.223.671 |
Chemical and physical data | |
Formula | C24H25FO5S |
Molar mass | 444.52 g·mol−1 |
3D model (JSmol) | |
Melting point | 98 °C (208 °F) |
| |
| |
NY (what is this?) (verify) |
Common side effects include vaginal yeast infections, nausea, constipation, and urinary tract infections.[2] Serious side effects may include low blood sugar, Fournier's gangrene, leg amputation, kidney problems, high blood potassium, and low blood pressure.[2] Diabetic ketoacidosis may occur despite nearly normal blood sugar levels.[2] Use in pregnancy and breastfeeding is not recommended.[1] Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor.[2] It works by increasing the amount of glucose lost in the urine.[2]
Canagliflozin was approved for medical use in the United States, in the European Union, and in Australia in 2013.[2][3][4][5] It is on the World Health Organization's List of Essential Medicines.[6]